Monkey Pox 'Emergency': Follow the Money

and find the usual suspects...(shocker)

Joel Walbert

Aug 18, 2024

Buy Me a Coffee

Strike.Me

Greetings fellow Plebs & Peasants,

You can read into this as much or as little as you want, but the timing and location of this is quite curious. I personally do not believe in coincidences, especially $1.2 billion coincidences.

- jw

#donotcomly #nocompromise #nosurrender

African Vaccine Manufacturing Accelerator (AVMA)

What is AVMA?

The African Vaccine Manufacturing Accelerator (AVMA) is a financing mechanism established to make up to US$ 1.2 billion available over ten years commencing with AVMA’s launch in June 2024 to accelerate the expansion of commercially viable vaccine manufacturing in Africa.
AVMA offers a ‘pull financing mechanism’ by providing downstream incentives to manufacturers to help offset initial costs of development and production.
The instrument was approved by the Gavi Board in December 2023 and launched in June 2024, following a design process conducted over nearly two years of close collaboration between Gavi, the African Union and the Africa Centres for Disease Control and Prevention (Africa CDC), with extensive consultations with partners, donors, industry, civil society and other stakeholders.

Why is it important?

The COVID-19 pandemic brought the strategic importance of access to vaccines and supply resilience into the public eye, and to the forefront of the minds of policymakers. No region felt the negative effects of COVID-19 vaccine inequity more than Africa, and no region stands to benefit more from sustainable growth in its vaccine manufacturing sector.
At present, demand for vaccines in Africa is valued at over US$ 1 billion annually, with this figure projected to grow along with the continent’s population over the next several decades. Africa already accounts for around 20% of the world’s population, yet the continent’s vaccine industry provides only around 0.1% of global supply.
Due to the high startup costs for vaccine manufacturing, the commercial sustainability required for ongoing supply security is unlikely to develop without downstream incentives. AVMA aims to contribute to two overarching objectives:
- a sustainable African manufacturing base that contributes to healthy global vaccine markets; and
- improved pandemic and outbreak vaccine supply resilience in Africa.

continued…